Risk factors for mortality in severe COVID-19: Exploring the interplay of immunomodulatory therapy and coinfection.

Risk factors for mortality in severe COVID-19: Exploring the interplay of immunomodulatory therapy and coinfection.

Publication date: Sep 17, 2023

Patients with severe clinical manifestations of coronavirus disease 2019 (COVID-19) present particular diagnostic and management challenges to critical care physicians, including identifying and responding to concurrent bacterial and fungal coinfections. This study evaluates risk factors for in-hospital mortality in patients admitted to the intensive care unit with severe COVID-19 during circulation of the B. 1.617. 2 (Delta) variant, including the impact of immunomodulators and bacterial and/or fungal coinfection. This retrospective cohort study enrolled patients with severe COVID-19. A Cox proportional hazard ratio analysis identified risk factors for in-hospital mortality. Outcomes were also compared between patients receiving and not receiving immunomodulatory therapy alongside standard care. Ninety patients admitted to the intensive care unit were enrolled. On multivariate analysis, the greatest risk factors for in-hospital mortality were invasive mechanical ventilation (hazard ratio (HR)ā€‰=ā€‰15. 27; 95% confidence interval (CI) 3. 29-71. 0; Pā€‰

Concepts Keywords
Coronavirus coinfection
Fungal COVID-19
Immunomodulatory critical care
Mortality immunomodulation
Ninety SARS-CoV-2

Semantics

Type Source Name
disease MESH COVID-19
disease MESH coinfection

Original Article

(Visited 2 times, 1 visits today)